
Newron Pharmaceuticals SpA
SIX:NWRN

Net Margin
Newron Pharmaceuticals SpA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
IT |
![]() |
Newron Pharmaceuticals SpA
SIX:NWRN
|
139.5m CHF |
31%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
735.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
202.1B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
178.4B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
205.3B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.9B USD |
13%
|
Newron Pharmaceuticals SpA
Glance View
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Newron Pharmaceuticals SpA's most recent financial statements, the company has Net Margin of 30.8%.